Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobiological Effect of 5-HT2AR Modulation (NeuroPharm2)
NCT03289949Phase 1Recruiting
- Start
- Mar 2017
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of psilocybin in major depressive disorder (MDD). Started Mar 2017; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03289949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289949.